You can consider me full blown crypto-Fly now; but not because I want to buy Bitcoin at $16,000 — but because I am enthralled by a brand new investor class that is teeming with exuberance. While I might be stubborn and a little old fashioned (I do smoke a pipe), I’m certainly not an idiot and have a good sense about the general direction of things. I intend to create a suite of financial products and tools for the crypto-space, which will be offered open source (free) to all of those interested. Unlike equities, there is a wide open gap in education and general information about tokens and coins. Being the generous man that I am, I intend to arb that ignorance and make a horse-race out of it. Considering we have over a decade in providing the good folks around here with a top shelf Market Intelligence Platform for equities, fitted with predictive mean reversion algorithms, I believe we are better suited than most to tackle this issue.
Stay tuned for details in the weeks to come.
European markets are flat, but WTI is higher again by 0.7%. I’m thinking there’s something brewing in crude. It might be worthwhile to buy some dog shit oils into Xmas.
Futures are higher and I’m looking at the biggest gambles known to mankind just before year end. Starting 2018, I will most likely invest exclusively via my quantitative tools, making adjustments once per month to reduce churn. The goal here is to automate my retirement. Considering I’m only 41, I have time to develop these methods and strategies. It will be a great help to be actively managing again, which I also intend to do.
Here are some other headlines worth your perusal.
Vail Resorts initiated with a Buy at Deutsche Bank; tgt $265
Digital Power Corporation launches new business division dedicated to the mining of cryptocurrencies
Honeywell sees FY18 EPS $7.55-7.80 vs $7.79 Capital IQ Consensus Estimate
State Street upgraded to Outperform from Mkt Perform at Keefe Bruyette
O’Reilly Auto upgraded to Outperform from Sector Perform at RBC Capital Mkts
Huntsman resumed with a Overweight at JP Morgan; tgt $36
Accuray downgraded to Underweight from Neutral at JP Morgan
Aimmune Therapeutics initiated with a Overweight at Cantor Fitzgerald; tgt $55
Morgan Stanley upgraded to Outperform from Mkt Perform at Keefe Bruyette
Intercept Pharma, Vertex Pharma (VRTX) both initiated with Buy ratings at Deutsche Bank
Honeywell updates Q4 guidance, issues FY18 outlook ahead of investor conference call